Imagene AI closed a $23 million Series B financing round led by Oracle CTO Larry Ellison to advance multi-modal digital pathology foundation models that integrate histopathology, molecular profiles, and clinical data for precision medicine. The company expanded collaborations including a partnership with Tempus AI to deliver rapid, AI-based biomarker prediction assays in oncology. Such initiatives exemplify AI’s accelerating role in streamlining clinical trials and personalized treatments.